Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -82.12% is 60% below its 5-year average of -51.24%, near the low end of its 5-year range (-82.12%–-26.92%).
As of the fiscal period ended Tuesday, June 30, 2026. 16.47% below its 12-month average of -70.50%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -82.12%.
RETURN ON EQUITY (ROE)
-82.12%
RETURN ON EQUITY (ROE) AVG TTM
-70.50%
RETURN ON EQUITY (ROE) AVG 3Y
-57.31%
RETURN ON EQUITY (ROE) AVG 5Y
-51.24%
RETURN ON EQUITY (ROE) AVG 10Y
-49.81%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-16.47%
CURRENT VS 3Y AVG
-43.29%
CURRENT VS 5Y AVG
-60.26%
CURRENT VS 10Y AVG
-64.85%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-38.51%
median of 487 covered companies
CURRENT VS SECTOR MEDIAN
-113.23%
vs the sector median at left
Fate Therapeutics, Inc.
Market Cap
$279.74M
Return on Equity (ROE)
-82.12%
TTM Avg
-70.50%
3Y Avg
-57.31%
5Y Avg
-51.24%
Market Cap
$281.16M
Return on Equity (ROE)
-27.36%
TTM Avg
-12.73%
3Y Avg
-30.52%
5Y Avg
-39.12%
Market Cap
$274.05M
Return on Equity (ROE)
-135.62%
TTM Avg
-521.17%
3Y Avg
-307.05%
5Y Avg
43.03%
Market Cap
$275.02M
Return on Equity (ROE)
-21.41%
TTM Avg
-11.72%
3Y Avg
-50.56%
5Y Avg
-98.46%
Market Cap
$286.40M
Return on Equity (ROE)
-49.11%
TTM Avg
-50.02%
3Y Avg
-153.47%
5Y Avg
-149.41%
Market Cap
$287.58M
Return on Equity (ROE)
-56.36%
TTM Avg
-35.98%
3Y Avg
25430.43%
5Y Avg
20391.58%
Market Cap
$265.63M
Return on Equity (ROE)
-124.67%
TTM Avg
-101.06%
3Y Avg
-69.44%
5Y Avg
-56.33%
Market Cap
$290.87M
Return on Equity (ROE)
-135.50%
TTM Avg
-129.54%
3Y Avg
-84.04%
5Y Avg
-77.00%
Market Cap
$266.50M
Return on Equity (ROE)
-38.33%
TTM Avg
-61.68%
3Y Avg
-393.03%
5Y Avg
-278.88%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fate Therapeutics, Inc. (FATE) | $279.74M | -82.12% | -70.50% | -57.31% | -51.24% |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.16M | -27.36% | -12.73% | -30.52% | -39.12% |
| Indaptus Therapeutics, Inc. (INDP)vs › | $274.05M | -135.62% | -521.17% | -307.05% | 43.03% |
| Aurora Cannabis Inc. (ACB)vs › | $275.02M | -21.41% | -11.72% | -50.56% | -98.46% |
| Abeona Therapeutics Inc. (ABEO)vs › | $286.40M | -49.11% | -50.02% | -153.47% | -149.41% |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $287.58M | -56.36% | -35.98% | 25430.43% | 20391.58% |
| AC Immune S.A. (ACIU)vs › | $265.63M | -124.67% | -101.06% | -69.44% | -56.33% |
| Larimar Therapeutics, Inc. (LRMR)vs › | $290.87M | -135.50% | -129.54% | -84.04% | -77.00% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $266.50M | -38.33% | -61.68% | -393.03% | -278.88% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $264.73M | -39.55% | -28.46% | -79.02% | -63.95% |
ROE
-82.1%
ROA
-48.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -82.12% |
| 2026-03-31 | -72.29% |
| 2025-12-31 | -65.79% |
| 2025-09-30 | -66.69% |
| 2025-06-30 | -65.63% |
| 2025-03-31 | -60.98% |
| 2024-12-31 | -58.44% |
| 2024-09-30 | -49.19% |
| 2024-06-30 | -44.26% |
| 2024-03-31 | -44.60% |
| 2023-12-31 | -43.68% |
| 2023-09-30 | -42.99% |
| 2023-06-30 | -48.33% |
| 2023-03-31 | -49.20% |
| 2022-12-31 | -58.21% |
| 2022-09-30 | -56.75% |
| 2022-06-30 | -43.71% |
| 2022-03-31 | -36.75% |
| 2021-12-31 | -31.25% |
| 2021-09-30 | -26.92% |
| 2021-06-30 | -28.19% |
| 2021-03-31 | -23.41% |
| 2020-12-31 | -45.10% |
| 2020-09-30 | -35.01% |
| 2020-06-30 | -24.57% |
| 2020-03-31 | -51.05% |
| 2019-12-31 | -40.10% |
| 2019-09-30 | -32.04% |
| 2019-06-30 | -59.63% |
| 2019-03-31 | -49.52% |
| 2018-12-31 | -41.50% |
| 2018-09-30 | -36.26% |
| 2018-06-30 | -109.93% |
| 2018-03-31 | -72.25% |
| 2017-12-31 | -55.65% |
| 2017-09-30 | -83.93% |
| 2017-06-30 | -66.01% |
| 2017-03-31 | -55.14% |
| 2016-12-31 | -45.74% |
| 2016-09-30 | -129.93% |
| 2016-06-30 | -134.54% |
| 2016-03-31 | -99.22% |
| 2015-12-31 | -78.85% |
| 2015-09-30 | -63.96% |
| 2015-06-30 | -55.79% |
| 2015-03-31 | -126.04% |
| 2014-12-31 | -91.33% |
| 2014-09-30 | -75.62% |
| 2014-06-30 | -62.72% |
| 2014-03-31 | -53.85% |
| 2013-12-31 | -41.09% |
